GE HealthCare's Photonova Spectra Photon-Counting CT Receives CE Mark, to Be Commercialized in Countries Recognizing CE Marking

On August 31, GE HealthCare announced that its advanced photon-counting computed tomography (PCCT) system, Photonova Spectra, has received CE marking. The system utilizes GE HealthCare's proprietary Deep Silicon™ detector technology. This certification will expand the system's availability in countries and regions that recognize the CE mark and pave the way for its clinical use.

According to reports, Photonova Spectra is designed to address the growing patient volumes and increasing diagnostic complexity faced by healthcare institutions today, aiming to provide clinicians with clearer and more timely imaging information. Leveraging deep silicon detector technology, the system can acquire spectral and spatial imaging information in each scan, and achieve broad coverage through ultra-high-resolution imaging to accelerate acquisition speed and reveal subtle tissue changes, micro-lesions, and vascular structures.

GE HealthCare stated that the system supports multiple examinations with a single solution, helping clinicians gain greater confidence in disease detection, characterization, and monitoring, while reducing workflow complexity and improving examination efficiency. Johan de Mey, Head of Radiology at Universitair Ziekenhuis Brussel (UZ Brussel), noted that the properties of silicon semiconductor materials enable precise measurement of photon energy, thereby supporting advanced spectral imaging; the system also features a 0.23-second fast rotation speed and 80 mm detector coverage, facilitating rapid image acquisition with reduced motion artifacts.

In terms of application directions, Photonova Spectra's clinical potential spans neurology, oncology, musculoskeletal imaging, chest imaging, and cardiology. For example, in neurology, the system can be used to visualize microstructures such as the inner ear and differentiate gray and white matter in the brain; in oncology, its iodine imaging capability is designed to help distinguish relevant findings and support treatment monitoring; in cardiology, combined ultra-high-resolution and spectral imaging can be used for in-stent lumen assessment, plaque characterization, and myocardial evaluation.

The system is also designed to handle the massive data volumes generated by photon-counting CT. GE HealthCare stated that Photonova Spectra leverages the NVIDIA accelerated computing platform and CUDA-optimized reconstruction technology, processing up to 50 times more data than conventional CT, transforming rich spectral data into timely, clinically meaningful images while maintaining a relatively streamlined workflow.

In terms of research collaborations, GE HealthCare is partnering with UZ Brussel in Belgium and Rigshospitalet at the University of Copenhagen in Denmark to further evaluate Photonova Spectra's capabilities in cardiology, oncology, neurology, musculoskeletal imaging, low-dose imaging, tissue characterization, and spectral data applications. These collaborations may also open new research pathways for quantitative imaging, tissue characterization, and spectral biomarker development.

GE HealthCare stated that following the CE marking, the company will commence commercial activities in countries that recognize the CE mark. Previously, Photonova Spectra received U.S. Food and Drug Administration 510(k) clearance and Japanese regulatory approval in March 2026. The system is part of GE HealthCare's more than $5 billion innovation investment.